A comparison of ARMS and direct sequencing for EGFR mutation analysis and Tyrosine Kinase Inhibitors treatment prediction in body fluid samples of Non-Small-Cell Lung Cancer patients
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A comparison of ARMS and direct sequencing for EGFR mutation analysis and Tyrosine Kinase Inhibitors treatment prediction in body fluid samples of Non-Small-Cell Lung Cancer patients
Authors
Keywords
-
Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 30, Issue 1, Pages 111
Publisher
Springer Nature
Online
2011-12-06
DOI
10.1186/1756-9966-30-111
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer
- (2011) Qing Zhou et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy
- (2011) Vicki Leigh Keedy et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples
- (2010) Gillian Ellison et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors
- (2010) Marie Brevet et al. LUNG CANCER
- Circulating tumour cells in clinical practice: Methods of detection and possible characterization
- (2010) Marianna Alunni-Fabbroni et al. METHODS
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circulating tumour cells in cancer patients: challenges and perspectives
- (2010) Klaus Pantel et al. TRENDS IN MOLECULAR MEDICINE
- Single-Molecule Detection of Epidermal Growth Factor Receptor Mutations in Plasma by Microfluidics Digital PCR in Non-Small Cell Lung Cancer Patients
- (2009) T. K.F. Yung et al. CLINICAL CANCER RESEARCH
- Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non-Small Cell Lung Cancer
- (2009) Y. Kuang et al. CLINICAL CANCER RESEARCH
- Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer
- (2009) Chen He et al. INTERNATIONAL JOURNAL OF CANCER
- Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non–Small-Cell Lung Cancer
- (2009) Hua Bai et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma
- (2008) S-G. Wu et al. EUROPEAN RESPIRATORY JOURNAL
- Detection of Mutations inEGFRin Circulating Lung-Cancer Cells
- (2008) Shyamala Maheswaran et al. NEW ENGLAND JOURNAL OF MEDICINE
- Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer
- (2007) Xiaozhu Zhang et al. LUNG CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More